Rona Therapeutics (Shanghai) Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Rona Therapeutics (Shanghai) Co., Ltd. - overview
Established
2021
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Established in 2021 and based in Shanghai, China, Rona Therapeutics (Shanghai) Co. , Ltd. is a pharmaceutical company that focuses on the development of modular and programmable nucleic acid drugs. It was recognized as the National High-tech Enterprise.
The company cooperated with KeyMed Biosciences, Ennovabio, Sanofi, and other enterprises. Yibin Shi, the company's founder, graduated from Fudan University, used to serve as the head of new product strategy in the Asia-Pacific oncology field of Roche Pharmaceuticals and the consulting consultant at Zhisheng Consulting. In March 2025, it raised USD 25 million in pre-series B funding led by new investor Geuniom Group, with participation from other returning investors Lilly Asia Ventures, LongRiver Investments and BioTrack Capital. The company is mainly engaged in the research and development of nucleic acid drugs.
It has GAIA Hepatic Targeting platform, APOLLO Central Nervous Delivery platform, and Extrahepatic Systemic Drug Delivery platform. The main products are siRNA drugs for diseases such as metabolism, central nervous system, ophthalmology, and tumors. Including PCSK9 siRNA for hypercholesterolemia and APOC3 siRNA for mixed hyperlipidemia, which adopt a modular and programmable mode. The company generates revenue by providing nucleic acid drugs.
The company will use the funds to advance its delivery and chemical modification platform technologies, expand its siRNA clinical pipeline in cardiovascular metabolism and weight loss, and enhance its production capacity.
Current Investors
Lilly Asia Ventures, CMB International Asset Management, Lanting Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.ronatherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.